Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Corticosteroid
|
| gptkbp:administeredBy |
oral route
topical application intramuscular injection intravenous injection ophthalmic route |
| gptkbp:ATCCode |
gptkb:H02AB02
|
| gptkbp:brand |
gptkb:Ozurdex
gptkb:Decadron gptkb:DexPak gptkb:Maxidex |
| gptkbp:CASNumber |
gptkb:50-02-2
|
| gptkbp:contraindication |
hypersensitivity to dexamethasone
systemic fungal infection |
| gptkbp:discoveredBy |
gptkb:Philip_Showalter_Hench
|
| gptkbp:discoveredIn |
1957
|
| gptkbp:drugClass |
gptkb:Corticosteroid
anti-inflammatory agent immunosuppressant |
| gptkbp:eliminationHalfLife |
36-54 hours
|
| gptkbp:excretion |
gptkb:kidney
|
| gptkbp:hasMolecularFormula |
C22H29FO5
|
| https://www.w3.org/2000/01/rdf-schema#label |
dexamethasone
|
| gptkbp:includedIn |
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
topical intramuscular intravenous intra-articular intralesional intravitreal ophthalmic |
| gptkbp:sideEffect |
gptkb:bone
hypertension mood changes weight gain insomnia increased appetite hyperglycemia increased risk of infection |
| gptkbp:usedFor |
immunosuppression
treatment of COVID-19 anti-inflammatory therapy treatment of asthma treatment of cerebral edema treatment of certain cancers treatment of croup treatment of severe allergies |
| gptkbp:bfsParent |
gptkb:COVID-19
gptkb:COVID-19_pandemic |
| gptkbp:bfsLayer |
4
|